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Regeneration of damaged neurons in neurodegenerative disorders like cerebral palsy and spinal cord
injury is a major challenge. The possibility of replacing the non-functional neurons remains an attractive
but an unflinching approach. We describes a novel human embryonic cell (hESC) line that has been
developed in animal-free conditions during derivation and long-term culture. The absence of any xeno-
product makes it suitable for clinical cell therapy. The cell line has been derived using a patented
technology from a single, spare, throw-away fertilized ovum 24 to 48 hr after fertilization donated during
a regular in vitro fertilization cycle. The cells thus obtained are very small cells (50 nm-2.5 µm) procured
24 hr after fertilization. They harbor all the properties of hESCs and blastocysts and express pluripotent
stem cells markers like octamer-binding transcription factor 4, (sex determining region Y)-box 2, Nanog,
stage-specific embryonic antigen-4, trophoectoderm marker; keratin 18, beta-human chorionic
gonadotropin (negative), immune-regulatory marker; human leukocyte antigen G (negative), gene
activating marker 5-methylcytosin, and other markers like telomerase and α fetoprotein. We have also
explored the differentiation of neuronal cells by determining the lineage specific neuronal marker, Neu N.
This is the first report of culturing and maintaining hESCs obtained from 2-celled stage without providing
any culture feeder layer embryo. Further, these cell lines have proven to be effective for the treatment of
neuronal disorders.
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INTRODUCTION
Regenerative medicine helps improve the quality of life of
patients by utilizing body’s own cells, tissue and organs to
restore or establish lost functions(Kulbatski et al., 2005). The
technology targets to harness the intrinsic power of the body to
heal, and then accelerate this healing in a clinically relevant
manner. The regenerative potential of stem cells in
neurological disorders or injuries is being investigated in
various therapeutical aspects(Kulbatski et al., 2005). Stem cell
therapy has shown tremendous potential in treating diseases
like diabetes, traumatic brain injury, stroke, spinal cord injury
(SCI) Parkinson’s disease, Alzheimer’s disease, heart failure
and bone marrow failure in the past(Willerth, 2011, Cao et al.,
2013, Balakumaran et al., 2014, Dantuma et al., 2010). Adult
stem cells like mesenchymal stem cells (MSCs) which can give
rise to cartilage, bone and adipose cells (Prockop, 1997),
hematopoietic stem cells in bone marrow that produce all type
of blood cells(Worton et al., 1969), neural stem cells in the
brain that give rise to glial cells and neuronal cells (Reynolds et
al., 1992) and broncho-alveolar stem cells in the lungs that
produce alveolar epithelial cells and bronchus epithelial cells
have been often used to treat these conditions (Kim et al.,
2005). Embryonic stem (ES) cells have been used in
neurodegenerative diseases as a source of neuronal progenitors
which could potentially secrete regeneration promoting factors
or as a source of ES cells derived neurons and oligodendrocytes
to replace the lost neurons(Willerth, 2011, Shroff et al., 2014,
Shroff et al., 2014 ). Human embryonic stem cells (hESCs)
which have a remarkable property of pluripotency, self renewal
and differentiation can be a breakthrough technology aimed at
this direction. Due to its unmatched potential, FDA has also
given approval for the use of hESC based therapy for treatment
of SCI(Geron, 2009).
There is another category of small-sized stem cells (0.1 µm -5
µm) known as blastomeric like stem cells (BLSCs) and very
small embryonic like stem cells (VSELSCs) studied intensively
by different scientific groups(Bhartiya et al., 2014, HE). These
VSELSCs express pluripotency genes and differentiate into cell
types from germ layers in vitro; however they lack in vivo
evidence. A study reported that human VSELSCs differentiate
in to adipocytes, neurons, osteoblasts and chondrocytes. No
teratoma formation was observed (Havens et al., 2014).
In this paper, we report VSELSCs of pre-blastomeric origin
derived from 2-celled stage. These cells were taken from a
fertilized ovum (50 nm-2.5 µ in size) discarded in a regular in
vitro fertilization (IVF) cycle, with full consent from the donor.
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The safety and efficacy of the cell line has been
established(Shroff et al., 2015 b).We have used these cells to
treat over 1300 patients with diverse ailments including
diabetes, myocardial infarction, cerebral palsy, SCI, Lyme
disease, Spinocerebellar Ataxia, Friedrich’s Ataxia,
Alzheimer’s disease, Parkinson’s disease, autism and cerebral
palsy(Shroff et al., 2014, Shroff et al., 2014 , Shroff, 2015 d,
Shroff, 2015 e, Shroff et al., 2015 a, Shroff, 2015 c). No
teratoma formation has been observed till date.
Further, the paper describes culture technique which produces
hESC line free from animal products, feeder layers, growth
factors, leukemia inhibitory factor (LIF), supplementary
mineral combinations, amino acid supplements, fibroblast
growth factor, membrane associated steel factor, soluble steel
factor and conditioned media (United States Granted Patent No
US 8592, 208, 52). The present study also discusses the
characterization of hESC line for its pluripotent nature, its
differentiation into neuronal lineages and its use for the
treatment of neurological disorders. We have characterized the
hESC at molecular, cellular and functional level using scanning
electron microscopy (SEM), transmission electron microscopy
(TEM), confocal microscopy, reverse transcriptase polymerase
chain reaction (RT machines-PCR) and flow cytometry
analysis. The cell line has also been characterized based on
long-term proliferation and maintenance, karyotyping and in
vivo differentiation as teratoma formation assay. It has been
chromosomally stable since the year 2000 and for >4000
passages. The study also provides a composition of injectable
stem cells in ready to inject form that is simple to prepare, safe,
cost effective, efficient, easily transportable, scalable and has a
shelf life of six months.
MATERIAL AND METHODS
Ethics Statement
The work done was approved by an Independent Ethics
Committee (IEC). The institutional committee for stem cell
research and therapy of Nutech Mediworld, New Delhi, India
reported the clinical study to National Apex Committee for
Stem Cell Research and Therapy (NAC-SCRT). The study was
conducted in accordance to the Declaration of Helsinki in a
good clinical practices (GCP) compliant condition (Reynolds et
al., 1992). A verbal, written and video consent was provided by
the patient. The ethics committee approved this procedure of
obtaining the consent.
Good Practices in Stem Cell Culture Laboratory
The cells are cultured and maintained as per our in-house
patented technology (United States Granted Patent No US
8592, 208, 52) in a good manufacturing practice (GMP), good
laboratory practice (GLP) and good tissue practice (GTP)
compliant certified laboratory.
Origin of Cell Line
Directed neuronal cell line was obtained from a single, spare,
expendable, pre-implantation stage fertilized ovum taken
during natural IVF process with due consent.
Derivation and Culture of Expendable Cells
For derivation of cell line, a spare embryo obtained from IVF
procedure was suspended in a small amount of minimal
essential medium (RMPI with 2.2 g/L sodium bicarbonate) and
the hESCs were isolated from the embryo by mechanical
means (e.g. shaking). Additional medium (RPMI and
Dulbecco's Modified Eagle's Medium [DMEM; Himedia Labs,
Mumbai, India]) was added in separate flasks containing
isolated cells along with a β-hCG agonist (16-64 µl of 500
IU/ml, Serum Institute of India, Pune, India) and progesterone
(16-64 µl of 250 mg/ml, Sun Pharma, Mumbai, India) in
aerobic conditions. After 24 hr, 1 mL of the media containing
embryonic cells were transferred to a 40 mL cell culture
medium (RPMI and DMEM) containing progesterone and β-
hCG in a 50 mL container. The culture medium along with
stem cells was incubated in a horizontal position at ambient
temperature in an environment containing carbon- dioxide
(CO2). After 24 hr, the product was divided into two different
flasks and RPMI and DMEM were added separately in a ratio
of 1:3.5 to 1:35 volume by volume. The cells thus obtained
were re-incubated at 37oC in a water jacketed incubator with an
atmosphere of 3.5-6% CO2 to obtain the desired cell density.
During incubation, 0.1 μAmp to 1 mAmp current was given to
the cell culture for a short duration. The application of
microcurrent is crucial for maintaining the cells in their
undifferentiated and pluripotent stage. After reaching the cell
density of 107 to 108 cells per cubic centimeter, the cells were
separated with centrifugation. The detailed cell culture and
differentiation techniques have also been elaborated in our
patent document (detailed compositions comprising human
embryonic stem cells and their derivatives, methods of use, and
methods of preparation are available at
http://patentscope.wipo.int/search/en/WO2007141657). The
cells were then divided in to three aliquots- one aliquot was
reincubated in anaerobic condition with either DMEM or
RPMI; second aliquot was stored at freezing temperature and
the third aliquot was made ready to injection (RTI). The cells
were stored in a deep freezer after adding dimethyl sulphoxide
(DMSO, 0.2-2% w/v) to the culture medium. The level of
DMSO used is typically less than 1:1600. DMSO is used for
cryopreservation to avoid inducing differentiation or damage to
the cells.
Sample collection for Marker Study
The RTI was obtained after centrifuging the cells for 5 min at
1000 rpm and the pellet was suspended in normal saline
(Nirlife, Nirma Ltd. Ahmedabad, India). The frozen syringes of
cells were thawed by placing the syringes in between palms of
the hands till they attain the body temperature prior to marker
study. Characterization of expression of different stem cell
markers was done with different approaches including flow
cytometry, RT-PCR and immunoflourescence.
Sterility tests
A quality check was performed on the stored cell batches and
the cultured cells taken from GLP compliant laboratory which
included integrity, viability and microbial contamination. The
tests included those for HIV, HbsAg, conventional PCR for
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Koch’s test, chromosomal analysis by CG method of Giemsa
banding. The culture condition was tested by the manual
culture plate method and manual sensitivity. Identification with




Scanning electron microscopy was done to obtain information
about sample’s surface topology and composition which was
not possible in normal microscopic observation.
For SEM analysis, tissue was fixed in ½ Karnovsky’s Fixative
and OsO4. Following the fixation, the tissue was washed in
0.1M Cacodylate buffer. Then, the dehydrated tissue was
washed using a series of ethanol washes: 50% ethanol for 15 –
30 min, 70% ethanol for 15 – 30 min, 95% ethanol for 15 – 30
min, 100% ethanol for 15 – 30 min and finally, 100% ethanol
for 15 – 30 min. The tissue was immersed in pure
hexamethyldisilazane (HMDS) for 15 min, washed and again
immersed in pure HMDS. Afterwards, the sample was covered
with fresh HMDS and left under the hood until the HMDS
evaporates off. Specimens were ready to mount onto stubs and
sputter coated with Au/Pd in the morning or stored desiccated
until coated.
Transmission Electron Microscope
A transmission electron microscope is an analytical tool
allowing visualization and analysis of specimens in the order of
mm to nm range, which is thousands of times smaller than the
smallest resolvable object in a light microscope. For TEM
analysis, hESCs were centrifuged and suspended in phosphate
buffer saline (PBS; pH 7.3). The cells were fixed in 4%
glutaraldehyde for 2 hr and stored at 4º C for further use.
Afterwards, 200 µl of the sample was put onto formvar-coated
copper grids and allowed to settle for 20 min at room
temperature (RT). Excess PBS was removed by wicking with
filter paper before fixation using a 2% paraformaldehyde, 2%
glutaraldehyde, and 0.05 M phosphate solution for 2 min.
Grids were washed with distilled water followed by counter
staining with 1% phosphotungstic acid (PTA) for 1 min.
Samples were allowed to dry overnight at RT. Grids were
analyzed using a Technai G220 TEM (FEI, Hillsboro, OR) at
Advanced Instrumentation Research Facility (AIRF),
Jawaharlal Nehru University, New Delhi, India.
Phase Contrast Microscopy
Phase contrast microscopy helps view the transparent and non-
light absorbing specimens. A specialized type of phase-contrast
objective is added in the microscope. The light causes
destructive interference pattern in the image, making the details
in the image appear dark as opposed to the lighter background.
Prior to harvesting of the cells, they were kept in presence of
emecolcine for 2 hr. Subsequently, the cells were incubated at
37°C in 0.56% potassium chloride solution for 5 min. Then the
cells were fixed at 4°C for 15 min with methanol-acetic acid
fixative. This cell suspension was added onto semi-dry cold
glass slides and kept for 1 hr at RT to dry. The cells were then
stained with giemsa for 10 min before viewing neuronal cells
using phase contrast microscopy.
RNA Extraction and RT-PCR
A total of 2 x 106 to 3 x 106 cells were taken for PCR analysis.
Total RNA was isolated from hESCs using RNA easy mini kit
as per manufacturer kit protocol (RNA easy kit, Qiagen Inc.,
Valencia, CA, USA Cat No. 74104). The concentration and
purity of RNA was determined at 260/280 O.D. in a
spectrophotometer. RNA was converted into cDNA using oligo
(dT) primers with the help of SuperScript III Cells Direct
cDNA Synthesis System (Invitrogen, Cat. No.18080-051). The
cDNA synthesis was done by heating sample at 50ºC for 50
min followed by termination of reaction at 85ºC for 5 min.
Afterwards, the reaction mixture was cooled at 4ºC for 5 min.
Synthesized cDNA was treated with RNAse H for 30 min at
37ºC. PCR reaction was performed using cDNA as a template
with Paq5000 DNA polymerase (Agilent technologies, Cat No.
600680). Human -actin gene was used as a house keeping
control. The amplified PCR products of specific genes using
specific primers were analyzed by electrophoresis on 1%
agarose gels.
Table 1 Primer Sequence, size and reaction conditions for PCR cycles
Genes Primers Sequence Size Annealing temperature
-actin Forward ATCTGGCACCACACCTTCTACAATGAGCTGCG 800 bp 60oC
Reverse CGTCATACTCCTGCTTGCTGATCCACATCTGC
SSEA 4 Forward TGGACGGGCACAACTTCATC 118 bp 58oC
Reverse GGGCAGGTTCTTGGCACTCT
Sox 2 Forward CCCCCGGCGGCAATAGCA 48 bp 58oC
Reverse TCGGCGCCGGGGAGATACAT
Nestin Forward GAAACAGCCATAGAGGGCAAA 167 bp 58oC
Reverse TGGTTTTCCAGAGTCTTCAGTGA
Keratin 18 Forward CACA GTCTGCTGAGGTTGGA 164 bp 58oC
Reverse GAGCTGCTCCATCTGTAGGG
Oct 4 Forward CGACCATCTGCCGCTTTGAG 577 bp 58oC
Reverse CCCCCTGTCCCCCATTCCTA
Keratin 18 Forward CACA GTCTGCTGAGGTTGGA 164 bp 58oC
Reverse GAGCTGCTCCATCTGTAGGG
-HCG Forward ATGTGCAGGATTGCCCAGAA 510 bp 58oC
Reverse CCCCCATTACTGTGACCCTG
-HLAG Forward ATCATACTGACCTGGCAGCG 158 bp 58oC
Reverse CTGCACATGGCACGTGTATC
For all reactions, 35 cycles of PCR were performed.
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The primer sequence, annealing temperature, number of PCR
cycles and fragment size are provided in Table 1.
Flow Cytometry
Expression of different intracellular molecules and surface
markers were determined through fluorescence-activated cell
sorting (FACS). Single cell suspension at a concentration of
1x106 to 2 x106 was fixed in 4% paraformaldehyde for 20 min
at RT. After washing of cells with saline, permeabilization of
cells was done with 0.25% Triton X-100 for 20 min at RT.
Cells were washed twice and blocked with 5% bovine serum
albumin (BSA) (or 10% serum/Fc block receptors) for an hour
at RT. Cells were washed again and labeled with primary
antibodies Oct-3/4 (1:100, Santa Cruz), Nestin (1:100,
Neuromics), stage-specific embryonic antigen-4 (SSEA-4;
1:150, Abcam), keratin-18 (Krt-18;1:100, Abcam), SRY-
related HMG-box gene 2 (Sox2; 1/10, Abcam) and human
leukocyte antigen G (HLA-G; 1:100, Santa Cruz). Washed
cells were further labeled with secondary antibody- Alexa
fluor©488 donkey anti-mouse IgG (Invitrogen Life technology,
Cat No. R37114) or Alexa fluor©647 donkey anti-Mouse IgG
(1:200) (Invitrogen Life technology, Cat No. A-31571) for 30
min at RT. Cells were sorted on BD AccuriC6 flow cytometer
and analyzed with BD Accuri TM C6 Software (BD,
Biosciences).
Immunofluorescence/Confocal Microscopy
For immunostaining, cells at a concentration of 1 x 106 were
adhered (or cytospin or smear preparation) on to a polylysine
coated cover/ slip slide. After brief washing in PBS, samples
were fixed in 4% paraformaldehyde (PFA) for 10-20 min at
RT. The PFA-fixed cells were permeabilized in 0.25% Triton-
X at RT for 20 min. PBS washed cells were blocked with 2%
BSA and 5 % donkey serum for 2 hr. Cells were incubated with
primary antibodies Oct-3/4(1:100, Santa Cruz), Nestin (1:100,
Neuromics), SSEA-4 (1:150, Abcam), Krt-18 (1:100, Abcam)
for an hour at 37°C.
Washed cells were further labeled with secondary antibody-
Alexa fluor©488 donkey anti-mouse IgG (Invitrogen, Life
technology, Cat No. R37114) or Alexa fluor©647 donkey anti-
Mouse IgG (1:200) (Invitrogen, Life technology, Cat No. A-
31571) for 30 min at 37°C. After staining with secondary
antibody, cells were counterstained with 0.1-1 µg/ml 4', 6-
diamidino-2-phenylindole (DAPI) for 5 min. The
immunostained cells were mounted in ProlongR Gold antifade
(Life technologies, OR, USA) and images were evaluated first
under immunofluorescence microscope and then confocal
microscope.
RESULTS
Integrity, viability and microbial contamination
The viability testing of the cells is done by staining with
tryphan blue and propidium iodide and viewing under FACS.
Subsequent to the viability testing, these cells are frozen that
helps in maintaining the shelf life of these cells.
Scanning electron microscopy
SEM shows the clear morphology of hESCs (Figure 1). The
cell surfaces seem to be embossed and few cells exhibited
bulging relief.
Transmission electron microscope
Figure 2 is the image obtained through TEM for the cells.
Multi-layered colonies were observed. Numbers of cell layers
were highest in the center and flattened towards the periphery.
Small projections from the surface of the cells were also
observed.
Phase Contrast Microscopy
Phase contrast images of neuronal cells were obtained at 10 x
and 20 x. The images presented clearly show a neuron with a
nucleus. The image also shows the presence of a cellular
extension from the cell body referred to as axon. (Figure 3)
Figure 1 Determination of Size and Surface Morphology of Cells by SEM
(100000x)
Figure 2 Determination of Size and Surface Morphology of Cells by TEM
(500000x)
Figure 3 Image of the Neuron Obtained With Phase-Contrast
Microscopy
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Gene Expression Profile of Different Intracellular and
Surface Markers of hESCs Determined by RT-PCR
Distinction of different cell population can be done by
morphological and developmental criteria along with temporal
and spatial expression of marker gene (Noisa et al., 2012). To
determine the human origin of cells, we amplified human β-
actin gene from cDNA prepared from RNA of hESC.
Amplicon generated by RT-PCR (Figure 4) confirmed the
presence of human β-actin gene in this very small population of
cells and supported its human origin. After confirming their
origin, we checked the expression of various pluripotent stem
cell markers in hESCs including, OCT4, NANOG, Sox2,
SSEA-4, trophoectodermal marker Krt18, α-fetoprotein,
neuronal lineage specific markers like nestin (neuronal
progenital cells, NPCs) and NeuN (neuronal marker in
differentiated cells) and other important markers including
GFAP (astrocytes and glial marker), HLA-G (-ve) (a major
histocompatible factor), 5-methyl cytosine(-ve) (gene
activation marker), telomerase(+ve) (maintenance of genomic
integrity and pluripotency of stem cells) and β- human
chorionic gonadotropin (-hCG) (immune modulator) by RT-
PCR. We found the amplification of these markers which
indicates the presence of all these genes in hESCs at mRNA
level (Figure 4).
Expression Profile of Different Intracellular and Surface
Markers of hESCs Determined by Confocal Microscopy:
To characterize the pluripotent properties of hESCs, the hESCs
were stained with markers specific antibodies namely Oct4,
Sox2 and SSEA-4. The results showed labeling of transcription
factors; Oct4, Sox2 intracellular marker, Nestin, surface
marker; SSEA-4 and neuronal specific markers; Nestin and-
NeuN (Figure 5). Since cells are <2 µm, 100 x magnification
gave clear discrete images. These cells mostly appeared in
clumps because of their inherent property of clumping. They
appeared as small chunks of green and red stain in suspension
after staining. This pattern of staining in clumps corresponds to
immunofluorescence studies in many published articles of
hESCs (Lowell et al., 2006, Yu et al., 2008). To further clarify
that the staining is specific to cells, colocalized images were
obtained with DAPI and DIC (Figure 5). The staining of HLA-
G was found to be negative. The negative control did not show
any staining and appeared as a black image. These results
indicated the pluripotent nature of hESCs and lineage specific
differentiation into neuronal cells without any immune
response. The result showed label of transposition factor; Oct4,
neuronal marker; Nestin and surface marker; SSEA-4. Culture
also showed staining with Neu N which indicated the presence
of neuronal differentiating cell.
Cell Size versus Cell Debris
The cell size of our hESCs is variable and small (< 2 µm). The
minimum detectable particle size for BD Accuri C6 Flow
cytometry is 0.5 μm which acts as a limitation for the analysis
of the whole population of these cells. Threshold was used to
remove the debris and noise. In flow cytometry, the cells
having a cell size range from 0.5-2 µm have been read.
Expression Profile of Different Intracellular and Surface
Markers of hESCs Determined by Flow Cytometry
Undifferentiated hESCs express ES cell specific markers
similar to the cells in the inner cell mass (ICM). To determine
the expression of different progenitor markers in our hESCs,
flow cytometry was performed. The culture contains cluster of
many progenitor cells such as hematopoietic stem cell
progenitors, neuronal stem cell progenitors, MSC progenitors,
insulin producing stem cell progenitors, hepatocyte stem cell
progenitors, cardiac stem cell progenitors and epithelial stem
cell progenitors which can be seen by the presence of
respective progenitor markers. We focused our study on
identification of different pluripotency transcription markers
like Oct4, Sox2 and embryonic cell specific surface antigen;
including stage specific embryonic antigens like SSEA-4 and
Tra-1-81. The results showed that these hESCs express high
level of embryonic cell specific surface antigens SSEA-4
(Figure 6) but relatively no or very low expression of TRA-1-
81 (Figure 6) therefore, these hESCs can be proposed to be the
initial Tra-1-81(-) and SSEA-4(+) population representing the
cells of early neural differentiation. Another study has shown
Tra-1-81(-) and SSEA-4(+) cell population at early stage neural
differentiation of hESCs which further strengthened our
findings (Noisa et al., 2012). The expression of pluripotent
marker gene, Oct4 seems to be downregulated as not found in
Figure 4 Determination of Expression of Different Pluripotent Markers in
hESC by RT-PCR
Figure 5 Determination of Expression of Different Pluripotent Markers
in hESC by Confocal Microscope (100x)
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FACS analysis (Figure 6). However, Sox2, another known
pluripotent marker, was consistently expressed but the
expression remained low (Figure 6). These hESCs expressed
neuronal progenitor nestin but the expression and number of
cells positivity for nestin remained low (Figure 6).
Trophodermal marker krt-18 was expressed by a small
population and the level of expression per cell remained high.
We also found the negative staining of cells with
immunomodulatory marker, HLA-G. These results show that
our hESCs are capable of generating both neural and non-
neural lineage cell types.
DISCUSSION
The fertilization of mammalian oocyte by sperm takes place in
the ampulla of the oviduct(Coy et al., 2012). Post fertilization,
the embryo undergoes a number of events such as fusion of
paternal and maternal pronuclei, global demethylation,
cleavage of cells, embryonic genome activation (EGA) and
epigenetic reprogramming(Morgan et al., 2005). As the
pronuclei fuse, maternal proteins inherited from oocyte
cytoplasm causes the first cleavage of the cell to produce a 2-
cell stage. The cleavage of the embryo neither occurs
exponentially from 2-cell to 4-cell to 8-cell at regular time
intervals nor is monitored by time, but by the maternal genes
and activation of genome of the embryo as the cleavage
progresses. By day 3, (72 hrs) embryo reaches to 16-cell
morula stage which marks a major event of compaction
wherein cells closely arrange themselves within zona pallucida,
associate tightly and establish tight junctions with each
other(Trounson et al., 1982). This event is considered as the
first step towards differentiation. Before this event, each cell in
an embryo is considered totipotent which is capable of
producing a whole organism (Mitalipov et al., 2009). By the
morula stage, major epigenetic modifications and EGA has
already taken place(Chavez et al., 2014). Blastomeric cells
derived from ICM of blastocyst are pluripotent in nature and
are termed as hESCs, and maintain their stemness through an
intricate array of regulatory proteins and surface markers like
Oct4, Sox2, Nanog and surface markers SSEA-4 and TRA1-81
also serve as markers of pluripotency(Cauffman et al., 2009,
Rizzino, 2009). Maintaining an undifferentiated state during in
vitro culture and differentiating into all kinds of cells in human
body has opened the opportunity to use hESCs in clinical
transplantation. However, the use of hESCs in clinical
applications has limitations of its distinction from the other cell
types, particularly tumor cells, to avoid potential risk of
teratoma formation.
Although, hESCs have been cultured in well-defined
populations in vitro but majority of hESCs methodology of
derivation and/or propagation includes indirect or direct
exposure to the animal material. Transplanting of such
contaminated hESCs to patients will be associated with risks of
graft rejection and transfer of non-human pathogens which is
inappropriate for clinical use. However, a wide group of
researchers are working to establish a xeno-free system but
have failed to fully eliminate the animal products. Fewer
studies have further progressed by maintaining and expanding
undifferentiated hESC on human feeder free
layers(Klimanskaya I, 2005, Ludwig TE, 2006, Xu C, 2001 ,
Richards et al., 2002, Richards et al., 2003, Amit et al., 2003,
Bergström et al., 2011). Till date, majority of the methods
adopted for culturing hESCs have resulted in a loss of genomic
integrity as evidenced by numerous conventional karyotyping
studies, SNPs and CGHs arrays(Josephson et al., 2006 ,
Catalina et al., 2009). hESCs are mostly derived from ICM of
blastocyst embryos(Thomson et al., 1998) but attempts have
been made to derive these cells from single
blastomeres(Klimanskaya et al., 2006, Geens et al., 2009) and
8-celled stage morula embryos(Strelchenko et al., 2004 ). Till
date, no stable cell line has been derived from 2-cell stage of
embryos. Though attempts have been made but most of the cell
lines which are derived from pre-implantation embryos have
been derived from 5 to 8-cell stage embryos. The usual cell
lines are derived from a blastocyst which is 64 cells to 128
cells. The hESCs cultured at our facility hence provide a novel
cell line. It has been derived from 2-cell stage embryo, post
pronuclear fertilization and first cell division, grown in a
culture medium that does not contain supplements such as
basic fibroblast growth factor, leukemia inhibitory factor,
membrane associated steel factor, soluble steel factor, serum,
albumins or albumin supplements, amino acid supplements,
vitamin supplements, transferrins or transferring supplements,
antioxidants, insulin or insulin substitutes, collagen precursors
or collagen precursor substitutes, trace elements, residues or
“conditioned media”, animal products, feeder cells and growth
factors. During its derivation from 2-cell stage embryo, the
cells were found fragmented and on mechanical shaking the
cells along with small fragments dissociate in the media. It has
been hypothesized that some fragments retained some part of
nuclear DNA and are capable of growing in culture. Fragments
(with fragmentation > 35%) if transplanted are reported to
grow into a baby during IVF . But some fragments without
DNA have also been detected by negative DAPI, thiozole
orange or propidium iodide staining. Also, TEM images
showcase some fragments with no nucleus. These fragments
have been considered vesicles due to their small size and lack
of nucleus. Detailed study of these fragments and their growth
characteristics is beyond the scope of this paper. The
dissociated blastomers and fragments were cultured on media.
This day is called as Day “0” of hESC cell line. This cell line
was further differentiated and the cells being used for this paper
have been grown till day 2 of cell line. Analysis of further days
of cell line has shown the presence of more differentiated
markers.
Figure 6 Determination of Expression of Different Pluripotent Markers
in hESC by Flow Cytometry
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In this study, we have characterized very small cells (even less
than 1-2µm) that are human in origin and behave as stem cells.
The advantage of using these cells for therapeutic purpose is
their size and very high multiplication rate. Due to their very
small size, these cells are able to cross the barriers of the body
and thus access the sites of malfunction easily. With a few
exceptions, these cells behaved like previously reported
blastocyst derived like VSEL’s(HE).
Human origin of our cell line has been confirmed by the
amplification of human β-actin gene. In this study, we found
the expression of Oct4, Sox2, NANOG and SSEA-4 which are
pluripotent embryonic stem cell marker, Krt-18,
trophoactodermal marker are expressed in these cells at RNA
level. Apart from this, we have also found the expression of 5-
methylcytosine -negative, telomerase. Expression of alpha-
fetoprotein which is involved in the maintenance of
pluripotency of embryonic cells was confirmed by RT-PCR.
Oct4 is a POU domain containing transcription factor and is
found to be the earliest expressed transcription factor which
plays a crucial role in the murine pre-implantation
development(Willerth, 2011, Cao et al., 2013). Previously, it
has been shown that Oct4 expressed in ICM in murine
blastomere(Balakumaran et al., 2014, Dantuma et al., 2010)
acts as a transcription factor for many genes expressed in
pluripotent cells and thus associated with totipotency(Prockop,
1997, Worton et al., 1969, Reynolds et al., 1992). We found
that cell surface marker for ES cells; SSEA-4 is also expressed
in these cells (Figure 6) which are pluripotent in nature. Sox2 is
a transcription factor playing crucial role in pre-implantation in
mammalian development. Sox2 forms a complex with Oct4
and NANOG and plays a critical role in maintaining self
renewal state of the pluripotent ICM in embryo and ES cells
via Oct4 expression (Kim et al., 2005, Bhartiya et al., 2014,
HE). Previous studies have shown that the expression of Sox2
is developmentally regulated and present in ICM of blastomere,
primitive ectoderm, extra embryonic ectoderm and developing
nervous system(Cauffman et al., 2009, Rizzino, 2009,
Klimanskaya I, 2005). Sox2 is considered as the earliest marker
of inner cell prior to ICM formation(Ludwig TE, 2006).
Furthermore, we explored the expression of lineage specific
marker. We found the mRNA expression of neuronal specific
marker Neu N and Nestin; and GFAP that was confirmed by
RT-PCR in our cells (Figure 4). Nestin is considered as the
marker of multipotent neural stem cells in embryonic as well as
adult tissue(Xu C, 2001 , Richards et al., 2002). Nestin is found
in all parts of brain during embryogenesis. Nestin expressing
cells are present and proliferate in injured brain(Richards et al.,
2003). GFAP, which is a marker for the astrocytes and various
neurofilament proteins, was also detected by RT-PCR in our
cells. The expression of different immunomodulatory markers
like HLA-G, β-HCG, CXCR2 and α- fetoprotein responsible
for immune tolerance in pregnancy and required for the proper
development of genetically different fetus in maternal body
was observed to be expresses at mRNA level. We have also
found the expression of genomic integrity marker telomerase at
mRNA level.
After confirmation with RT-PCR, we investigated the
expression of these markers through immunostaining involving
FACS and immunofluorescence/confocal microscope. In FACS
analysis, we observed staining of Oct4, Sox2, and SSEA-4
pluripotent stem cells markers where as other markers were not
detected. Furthermore, confocal analysis results indicated the
expression of Oct4, Sox2, Nanog, SSEA-4, NeuN and Nestin
whereas other markers were not found to be expressed.
Expression of these ES cells markers further strengthens the
pluripotent nature of our cells. Expression of Neu N and nestin
indicated the neuronal differentiation of these cells. Those
markers which are present at RT-PCR level but not present at
immunostaining level indicates that either these markers are not
expressed at protein level or are not needed for maintenance of
its pluripotency during in vitro culture. For example, HLA-G
involved in immune tolerance during pregnancy and proper
development of genetically different fetus in mother body was
expressed at RT-PCR level but not present at protein
expression level. 5-methylcytosine which is highly methylated
at zygote level undergoes demethylation till blastocyst stage
which further undergoes methylation stage. Methylation leads
to activation of gene while demethylation leads to inactivation
of gene. In our study, we were not able to get methylation of
cytosine which indicates that genes are in inactive state and
maintained in pluripotent state without going in to
differentiation mode.
CONCLUSION
This study revealed a novel cell population which is human in
origin and behaves like ES cells and can be used for
regeneration. The cell line which is cultured from 2-celled
staged discarded embryo obtained during IVF procedure
expresses different pluripotent stem cells markers and can be
directed towards neuronal lineage. It has no immunogenicity,
making it an ideal candidate for allogeneic implantation. These
cells have been used as therapy for the treatment of patients
with neurodegenerative diseases or damage of brain or SCI and
many neurological conditions(Shroff et al., 2014, Shroff et al.,
2014 , Shroff et al., 2015 a, Shroff, 2015 c, Shroff, 2015 d,
Shroff, 2015 e).
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